Develops drugs for liver cancers and melanoma.
Jun 2026Revenue $95.4M/yrExpenses $97.2M/yr
No trend
Figures by year
When will Delcath Systems be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $95.4M and expenses $97.2M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $85.2M | $84.6M | $660K |
| Dec 2024 | $37.2M | $49.6M | −$12.4M |
| Dec 2023 | $2.06M | $40.2M | −$38.2M |
| Dec 2022 | $2.72M | $36.6M | −$33.9M |
| Dec 2021 | $3.56M | $28.1M | −$24.5M |
| Dec 2015 | $1.75M | $17.0M | −$15.2M |
| Dec 2014 | $1.07M | $20.4M | −$19.3M |
| Dec 2013 | $790K | $33.8M | −$33.0M |
| Dec 2012 | $346K | $54.2M | −$53.9M |
| Dec 2011 | $0.00 | $46.5M | −$46.5M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.